Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.8 PLN | +0.10% | -6.04% | -13.39% |
Sales 2024 * | 152M 37.75M | Sales 2025 * | 218M 54.08M | Capitalization | 1.15B 286M |
---|---|---|---|---|---|
Net income 2024 * | -161M -40.03M | Net income 2025 * | -119M -29.59M | EV / Sales 2024 * | 7.1 x |
Net cash position 2024 * | 73.62M 18.3M | Net Debt 2025 * | 18.41M 4.58M | EV / Sales 2025 * | 5.38 x |
P/E ratio 2024 * |
-12.5
x | P/E ratio 2025 * |
-11.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | +0.10% | ||
1 week | -6.04% | ||
Current month | -9.78% | ||
1 month | -12.32% | ||
3 months | -9.95% | ||
6 months | -24.43% | ||
Current year | -13.39% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 49.8 | +0.10% | 3,262 |
24-04-24 | 49.75 | -2.07% | 4,107 |
24-04-23 | 50.8 | -0.39% | 5,472 |
24-04-22 | 51 | -3.59% | 7,527 |
24-04-19 | 52.9 | -0.19% | 4,351 |
Delayed Quote Warsaw S.E., April 25, 2024 at 11:55 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.39% | 284M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- RVU Stock